Status:
RECRUITING
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Conditions:
HPV
Eligibility:
All Genders
9-13 years
Phase:
NA
Brief Summary
Every year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choo...
Detailed Description
The burden of Human Papillomavirus (HPV)-related disease in the US is substantial. A safe and effective vaccine has been available for \>10 years, yet the current rate of completion for the HPV series...
Eligibility Criteria
Inclusion
- Practices:
- Practices in Metro Denver, Colorado and Metro Los Angeles, California (specifically UCLA medical clinics and clinics affiliated with Children's Hospital of Orange County)
- Practices that have at least 60% of providers agree to participate
- Practices do not currently recommend HPV at 9-10 years.
- Practice must have at least 100 eligible patients age 9-13 years
Exclusion
- Practices with less than 100 eligible patients age 9-13 years
- Practices currently routinely recommend HPV vaccine at 9-10 years.
- Practices where less than 60% of providers agree to participate in the study.
- Patient Eligibility Criteria
- Patient age 9-13 years
- Seen at a participating practice in the last 3 years
- Due for at least 1 dose of HPV vaccine
Key Trial Info
Start Date :
December 23 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
3100 Patients enrolled
Trial Details
Trial ID
NCT04722822
Start Date
December 23 2019
End Date
April 1 2027
Last Update
October 21 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California at Los Angeles
Los Angeles, California, United States, 90095
2
University of Colorado
Aurora, Colorado, United States, 80045